Natera, Inc. $NTRA Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its holdings in Natera, Inc. (NASDAQ:NTRA) by 1.5% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 166,638 shares of the medical research company’s stock after selling 2,611 shares during the period. Rhumbline Advisers owned 0.12% of Natera worth $26,824,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in NTRA. Sound Income Strategies LLC lifted its stake in shares of Natera by 95.7% in the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock valued at $39,000 after purchasing an additional 110 shares during the last quarter. Quent Capital LLC purchased a new stake in Natera in the 3rd quarter valued at about $46,000. Hilltop National Bank lifted its position in Natera by 59.8% in the third quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock valued at $50,000 after buying an additional 116 shares during the last quarter. N.E.W. Advisory Services LLC boosted its stake in Natera by 256.8% during the second quarter. N.E.W. Advisory Services LLC now owns 314 shares of the medical research company’s stock worth $53,000 after buying an additional 226 shares during the period. Finally, Blue Trust Inc. boosted its stake in Natera by 23.1% during the third quarter. Blue Trust Inc. now owns 431 shares of the medical research company’s stock worth $69,000 after buying an additional 81 shares during the period. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Herm Rosenman sold 48,419 shares of the business’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $227.42, for a total transaction of $11,011,448.98. Following the completion of the transaction, the director owned 20,342 shares in the company, valued at approximately $4,626,177.64. The trade was a 70.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 85,299 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28. Following the completion of the transaction, the chief executive officer directly owned 127,881 shares in the company, valued at $29,504,704.32. This trade represents a 40.01% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 455,899 shares of company stock valued at $106,475,440 over the last ninety days. 5.63% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on NTRA shares. Canaccord Genuity Group restated a “buy” rating on shares of Natera in a report on Monday, January 12th. TD Cowen restated a “buy” rating on shares of Natera in a research note on Wednesday, January 7th. Morgan Stanley raised their price target on Natera from $220.00 to $265.00 and gave the stock an “overweight” rating in a research report on Monday, December 1st. BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price objective on the stock in a report on Monday, October 27th. Finally, Stephens increased their target price on Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $249.20.

Natera Price Performance

Shares of NASDAQ NTRA opened at $206.23 on Monday. The company has a market cap of $28.53 billion, a price-to-earnings ratio of -90.06 and a beta of 1.64. The stock’s 50-day moving average is $230.37 and its two-hundred day moving average is $199.48. Natera, Inc. has a 1-year low of $125.38 and a 1-year high of $256.36.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.